Q32 Bio Inc.(QTTB) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain ontrack for Q4'24, with topline data from both trials expected in December -- -- Enrollment ongoing in ADX-097 Phase 2 basket trial for complement mediated renal diseases, with topline data expected in 2H'25 and initial open-label data in 1H'25 -- -- Cash and cash equivalents of $89.1 million as of September 30, 2024 ...